Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232465 · ClinicalTrials.gov registry record
Impact of Sperm DNA Integrity on In Vitro Cycles
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 420
- Enrollment target
NCT01232465: Completed study, sponsored by Northwell Health.
NCT01232465 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 420 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01232465 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 420 participants
- Enrollment target
Study Summary
Sperm DNA integrity will be measured via the Toluidine Blue Assay (TBA) for patients undergoing In Vitro Fertilization (IVF); the study will determine correlations, if any, between IVF success and sperm DNA integrity.
Primary Outcome
detemining whether the sperm sample (tested for DNA integrity) used to insemenate IVF retrieved eggs, results in a live birth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-09 |
What the finished NCT01232465 record still lists
NCT01232465 is an observational study that tracks outcomes without assigning an intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01232465 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01232465 about?
NCT01232465 is a clinical study titled "Impact of Sperm DNA Integrity on In Vitro Cycles". Sperm DNA integrity will be measured via the Toluidine Blue Assay (TBA) for patients undergoing In Vitro Fertilization (IVF); the study will determine correlations, if any, between IVF success and sperm DNA integrity.
What is the current status of trial NCT01232465?
This trial is currently completed. The enrollment target is 420 participants. The study started on 2010-10. Estimated completion is 2013-09.
Who is sponsoring clinical trial NCT01232465?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia